z-logo
open-access-imgOpen Access
Developing Therapeutic Approaches to Tau, Selected Kinases, and Related Neuronal Protein Targets
Author(s) -
Virginia M.-Y. Lee,
Kurt R. Brunden,
Mike Hutton,
John Q. Trojanowski
Publication year - 2011
Publication title -
cold spring harbor perspectives in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.853
H-Index - 105
eISSN - 2472-5412
pISSN - 2157-1422
DOI - 10.1101/cshperspect.a006437
Subject(s) - frontotemporal lobar degeneration , neuroscience , tau pathology , tau protein , neuropathology , tauopathy , biology , kinase , frontotemporal dementia , function (biology) , drug discovery , alzheimer's disease , microbiology and biotechnology , disease , neurodegeneration , bioinformatics , dementia , medicine , pathology
A hallmark of the Alzheimer disease (AD) brain is the presence of inclusions within neurons that are comprised of fibrils formed from the microtubule-stabilizing protein tau. The formation of misfolded multimeric tau species is believed to contribute to the progressive neuron loss and cognitive impairments of AD. Moreover, mutations in tau have been shown to cause a form of frontotemporal lobar degeneration in which tau neuronal inclusions observed in the brain are similar to those seen in AD. Here we review the more compelling strategies that are designed to reduce the contribution of misfolded tau to AD neuropathology, including those directed at correcting a possible loss of tau function resulting from sequestration of cellular tau and to minimizing possible gain-of-function toxicities caused by multimeric tau species. Finally, we discuss the challenges and potential benefits of tau-directed drug discovery programs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom